PD-118057

• Catalog No.: P5624
• CAS Number: 313674-97-4
• M. F.: C21H17Cl2NO2
• M. W.: 386.27118
• Purity: ≥98% (HPLC)
• Storage: under inert gas

SYNONYMS

• IUPAC name: 2-({4-[2-(3,4-dichlorophenyl)ethyl]phenyl}amino)benzoic acid
• IUPAC Traditional name: 2-({4-[2-(3,4-dichlorophenyl)ethyl]phenyl}amino)benzoic acid
• Synonyms: 2-[[4-[2-(3,4-Dichlorophenyl)ethyl]phenyl]amino]benzoic acid

DATABASE IDS

• MDL Number: MFCD08705328
• PubChem SID: 24724580
• CAS Number: 313674-97-4

PROPERTIES

• Empirical Formula (Hill Notation): C21H17Cl2NO2
• Purity: ≥98% (HPLC)
• Apperance: light yellow solid
• Solubility: DMSO: soluble9 mg/mL
• GHS Signal Word: Warning
• GHS Hazard statements: H315-H319-H335-H413
• European Hazard Symbols: Irritant (Xi)
• Personal Protective Equipment: dust mask type N95 (US), Eyeshields, Gloves
• GHS Precautionary statements: P261-P305 + P351 + P338
• Risk Statements: 36/37/38
• Safety Statements: 26
• Storage Condition: under inert gas
• Storage Temperature: -20°C
• German water hazard class: 3

DETAILS

Description (English)

Biochem/physiol Actions
PD-118057 is an activator of ether-a-go-go-related (hERG) potassium channel. PD-118057 is a second identified hERG channel activator, a representative in the series of structural analogs; PD-118057 at 10 μM leads to a 111% current increase in rabbit ventricular wedge (in comparison RPR260243 leads to only a 15% increase at the same concentration);PD-118057, unlike RPR260243, does not have a major effect on gating or kinetic properties of this channel. PD-118057prevents and reverses QT interval prolongation; Compounds such as PD-118057 may offer new approach in the treatment of delayed repolarization conditions, which occur in inherited or acquired long QT syndrome and congestive heart failure

Description (简体中文)

Biochem/physiol Actions
PD-118057 is an activator of ether-a-go-go-related (hERG) potassium channel. PD-118057 is a second identified hERG channel activator, a representative in the series of structural analogs; PD-118057 at 10 μM leads to a 111% current increase in rabbit ventricular wedge (in comparison RPR260243 leads to only a 15% increase at the same concentration);PD-118057, unlike RPR260243, does not have a major effect on gating or kinetic properties of this channel. PD-118057prevents and reverses QT interval prolongation; Compounds such as PD-118057 may offer new approach in the treatment of delayed repolarization conditions, which occur in inherited or acquired long QT syndrome and congestive heart failure